In COVID-19 clinical update #84, Dr. Griffin discusses childrens’ antibody response to vaccination, phase 3 results of Novavax vaccine, heterologous vaccination, antithrombotic therapy, EUA for molnupiravir, phase 3 results of AZD7442, serum ferritin levels and outcomes, heparin therapy, and WHO strategy for global vaccination.

Hosts: Daniel Griffin and Vincent Racaniello Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

Antibody profiles after mRNA vaccination in children (bioRxiv)
Novavax vaccine phase 3 results (medRxiv)
Heterologous vaccine boosters (medRxiv)
Antithrombotic therapy outcomes (JAMA)
Molnupiravir EUA submitted (Merck)
AZD7442 phase 3 results (AstraZeneca)
Serum ferritin levels and disease outcome (JAMA)
Heparin efficacy (JAMA)
WHO strategy to vaccinate world (WHO)
Letters read on TWiV 817
Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv

TWiV 817: COVID-19 clinical update #84 with Dr. Daniel Griffin